Human Wharton's jelly mesenchymal stem cells promote skin wound healing through paracrine signaling

Stem Cell Research and Therapy

Volumn 5, Issue 1, 2014, Pages

  Arno, Anna I ^a,b   Amini Nik, Saeid ^b   Blit, Patrick H ^b   Al Shehab, Mohammed ^b   Belo, Cassandra ^b   Herer, Elaine ^c   Tien, Col Homer ^c   Jeschke, Marc G ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; DECORIN; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN I GENE; COLLAGEN III GENE; CONTROLLED STUDY; CULTURE MEDIUM; EPITHELIZATION; FEMALE; FIBROBLAST GROWTH FACTOR 2 GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA INDUCIBLE FACTOR 1 ALPHA GENE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; PRIORITY JOURNAL; SKIN FIBROBLAST; SKIN INJURY; TRANSFORMING GROWTH FACTOR BETA 2 GENE; VEGF GENE; WHARTON JELLY MESENCHYMAL STEM CELL; WOUND CLOSURE; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; FIBROBLAST; GENETICS; INJURIES; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PHYSIOLOGY; SKIN; WHARTON JELLY;

MURINAE;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; PARACRINE COMMUNICATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RE-EPITHELIALIZATION; SKIN; TRANSFORMING GROWTH FACTOR BETA2; WHARTON JELLY;

EID: 84899483240     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt417     Document Type: Article

References (35)

1. Aging, diabetes, and the public health system in the United States. Caspersen CJ, Thomas GD, Boseman LA, Beckles GL, Albright AL, Am J Public Health 2012 102 1482 1497 10.2105/AJPH.2011.300616 22698044
2. Mesenchymal stem cell therapy in skin: why and what for? Khosrotehrani K, Exp Dermatol 2013 22 307 310 10.1111/exd.12141 23614735
3. Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q, Cell Immunol 2012 278 35 44 10.1016/j.cellimm.2012.06.010 23121974
4. Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Hanson SE, Bentz ML, Hematti P, Plast Reconstr Surg 2010 125 510 516 10.1097/PRS. 0b013e3181c722bb 20124836
5. Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Nekanti U, Rao VB, Bahirvani AG, Jan M, Totey S, Ta M, Stem Cells Dev 2010 19 117 130 10.1089/scd.2009.0177 19619003
6. Effects of transplanted mesenchymal stem cells isolated from Wharton's jelly of caprine umbilical cord on cutaneous wound healing: histopathological evaluation. Azari O, Babaei H, Drakhsahnfar A, Nematollahi-Mahani SN, Poursahebi R, Moshrefi M, Vet Res Commun 2011 35 211 222 10.1007/s11259-011-9464-z 21340694
7. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, Boyd R, Trounson A, Am J Pathol 2009 175 303 313 10.2353/ajpath.2009.080629 19497992
8. The alleviation of acute and chronic kidney injury by human Wharton's jelly-derived mesenchymal stromal cells triggered by ischemia-reperfusion injury via an endocrine mechanism. Du T, Cheng J, Zhong L, Zhao XF, Zhu J, Zhu YJ, Liu GH, Cytotherapy 2012 14 1215 1227 10.3109/14653249.2012.711471 22920838
9. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Tsai PC, Fu TW, Chen YM, Ko TL, Chen TH, Shih YH, Hung SC, Fu YS, Liver Transpl 2009 15 484 495 10.1002/lt.21715 19399744
10. Promising new potential for mesenchymal stem cells derived from human umbilical cord Wharton's jelly: sweat gland cell-like differentiative capacity. Xu Y, Huang S, Ma K, Fu X, Han W, Sheng Z, J Tissue Eng Regen Med 2012 6 645 654 10.1002/term.468 21916019
11. Proangiogenic features of Wharton's jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. Choi M, Lee HS, Naidansaren P, Kim HK,Cha JH, Ahn HY, Yang PI, Shin JC, Joe YA, In t J Biohem Cell Biol 2013 45 560 570 10.1016/j.biocel.2012.12.001
12. Mesenchymal stromal cells of human umbilical cord Wharton's jelly accelerate wound healing by paracrine mechanisms. Shohara R, Yamamoto A, Takikawa S, Iwase A, Hibi H, Kikkawa F, Ueda M, Cytotherapy 2012 14 1171 1181 10.3109/14653249.2012.706705 22900957
13. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG, Stem Cells Dev 2010 19 491 501 10.1089/scd.2009.0192 19635009
14. Stem cell therapy: a new treatment for burns? Arno A, Smith AH, Blit BH, Al-Shehab M, Gauglitz GG, Jeschke MG, Pharmaceuticals 2011 4 1355 1380 10.3390/ph4101355
15. Stem cells and tissue engineering in wounds and burns. Blit PH, Arno AI, Jeschke MG, Stem Cells Handbook New York: Springer, Snell S, 2013 399 410
16. Pax7 expressing cells contribute to dermal wound repair, regulating scar size through a β-catenin mediated process. Amini-Nik S, Glancy D, Boimer C, Whetstone H, Keller C, Alman BA, Stem Cells 2011 29 1371 1379 21739529
17. Wound healing and its impairment in the diabetic foot. Falanga V, Lancet 2005 366 1736 1743 10.1016/S0140-6736(05)67700-8 16291068
18. Cutaneous wound healing: recruiting developmental pathways for regeneration. Bielefeld KA, Amini-Nik S, Alman BA, Cell Mol Life Sci 2013 70 2059 2081 10.1007/s00018-012-1152-9 23052205
19. Less collagen production in smokers. Jorgensen LN, Kallehave F, Christensen E, Siana JE, Gottrup F, Surgery 1998 123 450 455 10.1016/S0039-6060(98)70167-9 9551072
20. Impaired wound healing. Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF, Clin Dermatol 2007 25 19 25 10.1016/j.clindermatol.2006.12.005 17276197
21. Dressings for superficial and partial thickness burns. Wasiak J, Cleland H, Campbell F, Spinks A, Cochrane Database Syst Rev 2013 3 D002106 23543513
22. Mechanisms of action of mesenchymal stem cells in cutaneous wound repair and regeneration. Li H, Fu X, Cell Tissue Res 2012 348 371 377 10.1007/s00441-012-1393-9 22447168
23. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Hocking AM, Gibran NS, Exp Cell Res 2010 316 2213 2229 10.1016/j.yexcr.2010.05.009 20471978
24. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Anzalone R, Lo Iacono M, Corrao S, Magno F, Loria T, Cappello F, Zummo G, Farina F, La Rocca G, Stem Cells Dev 2010 19 423 438 10.1089/scd.2009.0299 19958166
25. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Bongso A, Fong CY, Stem Cell Rev 2013 9 226 240 10.1007/s12015-012-9418-z 23233233
26. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Hass R, Kasper C, Bohm S, Jacobs R, Cell Commun Signal 2011 9 12 10.1186/1478-811X-9-12 21569606
27. Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV, Int J Mol Sci 2013 14 11692 11712 10.3390/ijms140611692 23727936
28. Wharton's Jelly stem cells: future clinical applications. Taghizadeh RR, Cetrulo KJ, Cetrulo CL, Placenta 2011 32 311 S315 21733573
29. Stimulation of skin and wound fibroblast migration by mesenchymal stem cells derived from normal donors and chronic wound patients. Rodriguez-Menocal L, Salgado M, Ford D, Van Badiavas E, Stem Cells Transl Med 2012 1 221 229 10.5966/sctm.2011-0029 23197781
30. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Wu Y, Chen L, Scott PG, Tredget EE, Stem Cells 2007 25 2648 2659 10.1634/stemcells.2007-0226 17615264
31. Promotion of cutaneous wound healing by local application of mesenchymal stem cells derived from human umbilical cord blood. Luo G, Cheng W, He W, Wang X, Tan J, Fitzgerald M, Li X, Wu J, Wound Rep Regen 2010 18 506 513 10.1111/j.1524-475X.2010.00616.x
32. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Hu JYX, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y, Endocr J 2013 60 347 357 10.1507/endocrj.EJ12-0343 23154532
33. First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Rasulov MF, Vasilchenkov AV, Onishchenko NA, Krasheninnikov ME, Kravchenko VI, Gorshenin TL, Pidtsan RE, Potapov IV, Bull Exp Biol Med 2005 139 141 144 10.1007/s10517-005-0232-3 16142297
34. Comparison of chemokine and receptor gene expression between Wharton's jelly and bone marrow-derived mesenchymal stromal cells. Balasubramanian S, Venugopal P, Sundarrai J, Zakaria Z, Majumdar AS, Ta M, Cythotherapy 2012 14 26 33 10.3109/14653249.2011.605119
35. Comparative evaluation of human mesenchymal stem cells of fetal (Wharton's jelly) and adult (adipose tissue) during prolonged in vitro expansion: considerations for cytotherapy. Christodoulou I, Kolisis FN, Papaevangeliou D, Zoumpourlis V, Stem Cells Int 2013 2013 246134 23533440